Table 2.
All-grade AEs occurring in ≥ 10% of patients and corresponding grades 3 and 4 AEs
| |
Everolimus 10 mg/day (n = 64) |
||
|---|---|---|---|
| AE, n (%) | All-grade | Grade 3 | Grade 4 |
| Anemia |
41 (64) |
10 (16) |
3 (5) |
| Hypertriglyceridemia |
35 (55) |
4 (6) |
0 (0) |
| Mouth ulceration |
34 (53) |
2 (3) |
0 (0) |
| Hyperglycemia |
33 (52) |
8 (13) |
0 (0) |
| Hypercholesterolemia |
32 (50) |
0 (0) |
0 (0) |
| Pyrexia |
26 (41) |
1 (2) |
0 (0) |
| Increased blood lactate dehydrogenase |
24 (38) |
1 (2) |
1 (2) |
| Fatigue |
20 (31) |
1 (2) |
0 (0) |
| Increased gamma-glutamyltransferase |
20 (31) |
7 (11) |
0 (0) |
| Rash |
20 (31) |
0 (0) |
0 (0) |
| Increased blood creatinine |
19 (30) |
0 (0) |
1 (2) |
| Cough |
18 (28) |
0 (0) |
0 (0) |
| Increased aspartate aminotransferase |
17 (27) |
0 (0) |
0 (0) |
| Increased alanine aminotransferase |
15 (23) |
1 (2) |
0 (0) |
| Epistaxis |
15 (23) |
1 (2) |
0 (0) |
| Hypocalcemia |
14 (22) |
0 (0) |
0 (0) |
| Interstitial lung disease |
14 (22) |
1 (2) |
0 (0) |
| Leukopenia |
14 (22) |
0 (0) |
0 (0) |
| Pruritus |
14 (22) |
0 (0) |
0 (0) |
| Peripheral edema |
13 (20) |
2 (3) |
0 (0) |
| Decreased platelet count |
13 (20) |
1 (2) |
0 (0) |
| Diarrhea |
12 (19) |
1 (2) |
0 (0) |
| Dyspnea |
12 (19) |
1 (2) |
4 (6) |
| Increased blood alkaline phosphatase |
11 (17) |
1 (2) |
0 (0) |
| Hypokalemia |
11 (17) |
0 (0) |
3 (5) |
| Lymphopenia |
10 (16) |
4 (6) |
0 (0) |
| Nasopharyngitis |
9 (14) |
0 (0) |
0 (0) |
| Dizziness |
8 (13) |
0 (0) |
0 (0) |
| Insomnia |
8 (13) |
0 (0) |
0 (0) |
| Increased blood creatine phosphokinase |
7 (11) |
0 (0) |
0 (0) |
| Decreased appetite |
7 (11) |
1 (2) |
0 (0) |
| Decreased hemoglobin |
7 (11) |
2 (3) |
0 (0) |
| Hyponatremia |
7 (11) |
5 (8) |
0 (0) |
| Nausea |
7 (11) |
0 (0) |
0 (0) |
| Upper respiratory tract infection |
7 (11) |
0 (0) |
0 (0) |
| Increased white blood cell count | 7 (11) | 0 (0) | 0 (0) |
AE, adverse event.